AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis
JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials
AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.
You may also be interested in...
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker